



默达生物成立于2021年8月，总部坐落在深圳市河套深港合作区内，并于2023年在香港科学园建立了转化医学研发中心。默达生物的META来自于“代谢”的英文单词Metabolism，也意味着我们对免疫代谢这个全新交叉的蓝海领域深度探索的愿景和决心。

默达生物是中国乃至亚洲唯一一家基于全新免疫代谢理论做原创药物的公司，这个全新的交叉学科正在为自身免疫疾病和肿瘤、代谢等疾病提供全新的解决思路。公司目前一共三条First-in-Class原创药物管线，核心管线计划将于明年在澳洲开展1期临床研究。公司的生物学团队由来自于康奈尔医学院-纪念斯隆凯特琳癌症中心的免疫生物学家组成，药物化学团队由拜耳前全球化学总监担任公司副总裁及化学负责人，领导多位业内资深药物化学专家，并利用AI药物设计来协助优化开发管线。默达生物的小分子药物，在临床前银屑病、多发硬化症、炎症性肠炎等疾病模型效果比目前FDA批准的一线治疗药物如JAK抑制剂、富马酸二甲酯对疾病进展和控制，以及安全性方面有显著改善。

默达生物过去一共从多家顶级风险投资和产业资本筹集了1500万美元，并正在进行新一轮2000万美元规模的融资，用于我们核心管线的全球临床研究。同时，默达生物也在积极探索潜在的合作对象，欢迎各位产业界合作伙伴和我们沟通。

META Pharmaceuticals Inc. (abbreviated as META), established in August, 2021 is located in the Shenzhen-Hong Kong Science and Technology Cooperation Zone, China. A new R&D center was inaugurated in Hong Kong Science Park (HKSTP) in 2023. The name “META” derives from the word “metabolism”, which symbolizes the company's primary focus on the interplay between metabolism and immunity.

META is the first pharmaceutical company in the Asia Pacific, dedicated to develop groundbreaking first-in-class drugs rooted in the innovative field of immunometabolism. This interdisciplinary approach provides innovative solutions for a wide range of health challenges, including autoimmune diseases, cancers, and metabolic disorders. Currently, the company has three pipelines, with the core pipeline slated to commence Phase 1 clinical trials in Australia next year. The team at META is composed of esteemed immunometabolism experts from Memorial Sloan Kettering Cancer Center, alongside former chemistry leaders from Bayer, Sanofi, and Wuxi Apptec. Notably, META's compounds have demonstrated remarkable improvements in mitigating disease progression in preclinical models of autoimmune diseases like psoriasis, multiple sclerosis and inflammatory bowel disease, outperforming FDA approved first-line treatments such as Tofacitinib and Tecfidera.

META has successfully secured \$15M in funding thus far and is actively seeking an additional \$20M in total funding to bolster its IND enabling studies and advance its Phase1 clinical trials. Moreover, META is actively exploring global development partnerships to further its mission.